AIT Therapeutics Reports Positive Top Line Results from its Nitric Oxide in Bronchiolitis (NO-BRO) Pilot Study in Infants

World News: . []

NEW YORK, June 13, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTC:AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced positive top line results from its Nitric Oxide in Bronchiolitis (NO-BRO) Pilot study.  Given these positive results, a pivotal study is expected to commence in the fourth quarter of calendar year 2019.

“Nitric oxide has once again been shown to improve the condition of patients with lung infections when delivered at a high concentration,” said Steven Lisi, Chairman and Chief Executive Officer of AIT Therapeutics.  “Our pivotal study in bronchiolitis patients, anticipated to start in the fourth quarter of calendar year 2019 and to complete in the second quarter of calendar year 2020 in the United States, will be performed using our proprietary nitric oxide generator and delivery system.  Reducing length of hospital stay in bronchiolitis patients benefits not only the patient and the parents, it reduces cost to the hospital as well.”

David Greenberg, M.D., Chairman of Pediatrics, and Head of the Pediatric Infectious Disease Unit at Soroka University Medical Center, and Principal Clinical Consultant of the study, stated, “today is a promising day for physicians and parents combatting bronchiolitis, which can lead to near-term and long-term respiratory complications.  Releasing infants from the hospital a day earlier is a huge relief for parents and caregivers, plus it allows the hospital to provide optimal care for more patients during the busy winter season.”  Dr. Greenberg further added, “I am looking forward to the day we can use inhaled nitric oxide for all of our bronchiolitis patients.”

The trial was a prospective, double blind, randomized, multi-center (6 sites), placebo-controlled study in 67 infants hospitalized with bronchiolitis.  All patients received standard-of-care (SOC) which consisted of oxygen, hydration and other typical treatments for bronchiolitis at the physician’s discretion.  In addition to SOC, the treatment arm received NO 160 ppm for 30 minutes five times per day for up to five days delivered via a breathing mask. 

Patients enrolled into the study were required to have a trial entry composite score of 7 – 10 using the modified Tal (mTal) score.  The mTal score has four components: 1) respiratory rate, 2) oxygen saturation (SaO), 3) accessory muscle use and 4) wheezing.  Each component is scored on a scale of 0-3. Other enrollment criteria included: age 12 months, gestation period of at least 28 weeks and acute bronchiolitis when admitted to the hospital, with an expected stay of at least 24 hours.

The primary endpoint of the study was hospital length-of-stay (LOS) as measured from the time of enrollment to the time of hospital discharge.  Secondary endpoints were safety, tolerability, time to mTal score 5 and time to SaO 92%.  With respect to the primary endpoint, to be discharged from the hospital a patient had to achieve an mTal score 5, have SaO 92% and have the physician sign the hospital discharge order. 

Table 1 shows the primary endpoint of hospital length of stay (LOS).  The mean difference in LOS between the NO treated patients v. control was 17.4 hours on an intent-to-treat (ITT) basis.  Using an adjusted intent to treat (aITT) analysis, the mean difference in LOS was 21.0 hours.  LOS for patients in the control arm was 35% longer than NO treated patients. 

There were protocol deviations for two patients: 1) an infant with a feeding tube was incorrectly enrolled in the study in the NO treatment arm, and 2) LOS was significantly increased in one patient in the control arm after treatment had been completed.  These two patients represent the only difference between the ITT and aITT analyses.  This study was not powered to show statistical significance.

There were no serious adverse events (SAEs) related to NO therapy.  NO treatment was well tolerated with no patient discontinuing treatment due to elevations in methemoglobin or nitrogen dioxide levels. 

Further data on the NO-BRO study will be presented at a future medical meeting. 

Bob Yedid LifeSci Advisors, LLC (646) 597-6989

 

More news and information about AIT Therapeutics, Inc.

Published By:

Globe Newswire: 21:30 GMT Wednesday 13th June 2018

Published: .

Search for other references to "therapeutics" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us
 

Advertising on SPi News: Information For Advertisers